Celcuity reports Q1 net loss $37.0M; VIKTORIA-1 WT data expected Q3 2025

Celcuity Inc.

2025-Q1 EPS reported -$0.86

Net loss of $37.0M ($0.86/sh) vs $21.6M ($0.64/sh) in Q1 2024; non-GAAP adj. net loss $34.7M ($0.81/sh).
Cash, cash equivalents and investments of ~$206M at March 31, 2025, expected to fund operations through 2026.
VIKTORIA-1 PIK3CA wild-type cohort topline data now anticipated in Q3 2025; mutant cohort data in Q4 2025.
VIKTORIA-2 Phase 3 first patient dosing on track for Q2 2025; CELC-G-201 Phase 1b data expected late Q2 2025.
Clinical trial collaboration initiated with Dana Farber and Mass General for gedatolisib in endometrial cancer.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.